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³3267$0$5,1'58*3ROMOTION SUPERHIGHWAY
2563(('75$3´
BETH E. WOLFE*
INTRODUCTION
Consider a child diagnosed with a rare and life-threatening disease.
Now, consider a pharmaceutical manufacturer that has tested a drug
and has evidence that it can cure that disease, but, while the Food
Drug $GPLQLVWUDWLRQ ³)'$´ KDVDSSURYHGWKDWGUXJIRURWKHUXses,
the FDA has not approved the drug for this new use. Would you
ZDQWWKDWFKLOG¶VSK\Vician to know about this? Would you care how
they learned about it? Are you willing to leave it up to a busy physician to spend countless hours researching in hopes of finding some
treatment that will work? Is it reasonable to expect this? Currently
pharmaceutical manufacturers are restricted in their ability to
promote uses of drugs that have not been approved by the FDA.1
Physicians are left to their own research to find possible drug
treatments for some of their most challenging patient illnesses.2
Recent challenges in the court may be about to change this.
Pharmaceutical manufacturers have been subjected to costly
lawsuits for the truthful promotion of off-label uses of drugs that
could save lives.3 The government has claimed billions of dollars
from pharmaceutical companies in settlement of claims for alleged
illegal promotion of uses of pharmaceuticals not approved by the
*Ms. Wolfe is a J.D. Candidate at North Carolina Central University School of
Law. She received her B.S. from the University of Michigan ± Dearborn, and her
M.B.A. from the Open University Business School in the United Kingdom.
1.Amarin Pharma, Inc. v. U.S. FDA, 119 F. Supp. 3d 196, 203 (S.D.N.Y. 2015).
2.Id. at 200.
3.C. Lee Ventola, MS, Off-Label Drug Information: Regulation, Distribution,
Evaluation, and Related Controversies, 34(8) Pharmacy & Therapeutics 428-440,
(2009), available at: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2799128/.
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FDA.4 This has been achieved by a provision based on criminal
misbranding under the Food, Drug, Cosmetic Act (FDCA).5 Any
drug that has been put into market and has been misbranded subjects
the manufacturer or their representative to penalties under the FDCA
including fines and imprisonment.6
Drug companies are now fighting back. In August 2015, the
Southern District of New York granted Amarin Pharma a preliminary
injunction preventing the FDA from prosecuting them for the
promotion of drug usages that were not approved by the FDA.7
Amarin wanted to promote their drug Vascepa, approved for one
patient population, for use by a different patient population for whom
the drug was not yet approved by the FDA.8 Amarin had already
completed testing that proved the effectiveness of this additional use,
DQGWKH)'$DJUHHGWKDWWKHWHVWLQJGLGVKRZWKHGUXJ¶VHIIHFWLYeness
for this new population.9 Amarin argued that preventing promotion
of truthful uses of their drugs is a violation of their free speech
rights.10 The United States District Court for the Southern District of
1HZ <RUN DJUHHG DQG JUDQWHG $PDULQ¶V DSSOLFDWLRQ IRU SUHOLPLQDU\
relief.11 This case is a victory for free speech and could expand the
availability of truthful and valuable uses of approved drugs to
physicians who might otherwise not have access. It could enable
crucial information to reach more physicians, so that they can use
drugs in patients where tKH GUXJ XVH IRU WKDW SDWLHQW¶V LOOQHVV PLJKW
otherwise be unknown. The question is ± does this open the door for
a flood of pharmaceutical manufacturers promoting all tested uses of
their product, or is it a trap for the unwary, allowing promotion of the
uses, but opening up the potential for suits under the FDCA?
This paper will look at the cases leading up to this decision, the
arguments that have won and lost, and the implications for the future.
It will examine if this is a victory for free speech or if it is a danger
4.Amarin Pharma, 119 F. Supp. 3d at 204.
5.See 21 U.S.C.S. § 331 (LEXIS 2011) (amended 2015).
6. Id.
7.Amarin Pharma, 119 F. Supp. 3d at 237.
8.Id. at 198.
9. Id.
10. Id.
11.Id. at 237.
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by usurping the authority of the FDA and allowing promotion
directly to physicians. It will also forecast the risks and rewards that
can be expected going forward. Will this put lifesaving cures into the
hands of physicians to treat those with little hope and extend,
improve, or save lives? Or will it open the floodgates for the
promotion of unapproved drugs, and fill the courts with lawsuits for
years to come, examining the fine line between truthful and hopeful
claims?
This article first reviews the 2015 Amarin Pharma, Inc. v. United
States FDA12 case and the events leading up to the challenge in court.
It then provides the background and history on drug approval,
labeling, and off label promotion, and the cases that have been settled
based on FDA prosecution for promotion of off label uses of drugs.
Next, it reviews the rationale behind the approval of the injunction
sought by Amarin based on the United States v. Caronia13 case from
2012. This case note then explores the benefits and arguments against
expanding allowable promotion of off label uses of drugs. Finally, it
argues that while this is a victory for first amendment protection of
free speech, drug makers should be wary of the risks of continued
prosecution as the holding may be found to be fact specific to
Amarin.
THE CASE
On May 7, 2015, Amarin Pharma, Inc. brought suit against the
United States Food and Drug Administration (FDA) seeking an
injunction against a threatened misbranding action under the Food,
Drug, and Cosmetic Act (FDCA) for its promotion of a triglyceride
lowering drug, Vascepa, for a use that was not approved by the
FDA.14
Vascepa is a drug developed to improve cardiovascular health.15
In 2011, Amarin sought FDA approval for two uses of Vascepa.16
The first use was for treating adult patients with very high
12.Id. at 196.
13.United States v. Caronia, 703 F.3d 149 (2d Cir. 2012).
14.Amarin Pharma, 119 F. Supp. 3d at 198.
15.Id. at 209.
16. Id.
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WULJO\FHULGH OHYHOV DERYH  PJ'/ RI EORRG DOVR FDOOHG ³VHYHUH
hypertriJO\FHULGHPLD´ 17 The second use was for treating patients
with persistently high triglyceride levels between 200 and 499 mg/dL
of blood and who were already on statin therapy. 18 The first use
received FDA approval on July 26, 2012.19 The FDA did not
approve the second use, and it is this use that was at issue in the case.
The FDA denied AmarLQ¶VDSSOLFDWLRQIRUWKLVXVHEHFDXVHDOthough
their studies proved that Vascepa was effective in reducing
triglyceride levels, there were studies that questioned whether this
subsequently reduced the risk of cardiovascular events.20
Vascepa has been shown to be effective in reducing triglyceride
levels.21 FDA-approved studies have been done confirming this, and
the FDA has agreed with this in correspondence with Amarin.22
Vascepa is also safe and can be safely used by people with severe
hypertriglyceridemia.23 Amarin gained agreement with the FDA to
conduct clinical trials testing whether Vascepa was effective for
WKRVH ZLWK SHUVLVWHQWO\ KLJK WULJO\FHULGHV RQ -XO\   ³WKH
unapSURYHGXVH´ 24 Additionally, this agreement for testing included
approval for testing other factors relevant to cardiovascular health.25
This study was called the ANCHOR Study.26 The agreement was an
)'$³VSHFLDOSURWRFRODVVHVVPHQW´ 63$DJUHHPHQW ZKLFKSURYLGHV
that if the study is done and the benchmarks set in the agreement are
met, that the FDA would approve the drug.27 At that time, the FDA
required, and Amarin agreed, that Amarin would later conduct a
study on whether Vascepa could prevent major cardiovascular events
in high-risk patients including those with persistently high
triglycerides.28 This study was called the REDUCE-IT Study, and
17. Id.
18. Id.
19. Id.
20. Id.
21.Id. at 213.
22.Id. at 209.
23. Id.
24.Id. at 210.
25. Id.
26. Id.
27. Id.
28. Id.
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the agreement was the REDUCE-IT SPA Agreement.29 The FDA
intended this later study to be underway to provide input before they
would approve the use of Vascepa for this patient population.30
The ANCHOR study achieved its benchmark requirements and
showed that Vascepa significantly reduced triglyceride levels in
patient populations with persistently high triglycerides.31 However,
after Amarin applied for approval for Vascepa for this use, the FDA
determined, through a public advisory committee convened in
October 2013, that while Vascepa reduced triglyceride levels in this
patient population, this had no impact on reducing risks of
cardiovascular events.32 As a result, despite Amarin meeting the
benchmark terms in the ANCHOR study, the FDA rescinded the
ANCHOR SPA agreement and would not approve Vascepa for usage
in this population unless this correlation could be proven.33 The FDA
claimed that other drugs that successfully reduced triglyceride levels
had failed to yield a reduction in cardiovascular events.34 They
claimed that reduction in cardiovascular events was a premise of the
ANCHOR study, and, therefore, it was appropriate to rescind that
SPA agreement.35 They further stated that if Amarin was able to
show a reduction in cardiovascular events from the REDUCE-IT
study, then these results could be used to satisfy the approval
³$PDULQ DSSHDOHG WKH UHVFLVVLRQ RI WKH
requirements.36
ANCHOR-SPA agreement through three successive levels of the
FDA reYLHZ´37
In addition to not approving Amarin for use for those with
persistently high triglyceride levels, the FDA told Amarin that they
would consider Vascepa to be misbranded under the FDCA 21
U.S.C.A. § 352 (West 2013),38 if the FDA marketed it for this use
29. Id.
30. Id.
31. Id.
32.Id. at 211.
33.Id. at 212.
34. Id.
35. Id.
36. Id.
37.Id. at 211.
38.See 21 U.S.C.S. § 352 (2007) (defines ways in which drugs will be deemed to
be misbranded including false or misleading labels and packaging).
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prior to any approval of this use.39 This was a clear threat of criminal
litigation under FDCA § 331 (prohibited acts).
On May 7, 2015 Amarin brought a first amendment challenge to
the Southern District of New York claiming the FDA was prohibiting
them from promoting truthful and non-misleading statements, citing
the results from the ANCHOR study.40 Amarin claimed that the
FDA restrictions on promotion significantly reduced their ability to
provide truthful information to physicians so that physicians could
determine whether to prescribe Amarin to patients with persistently
high triglycerides. 41 Amarin claimed that these prohibitions were a
violation of their first amendment rights to engage in truthful and
non-misleading speech.42 Further, they claimed that they should be
able to provide information about these trials and results and uses
without fear of criminal litigation.43 $PDULQ¶V UHOLHG RQ WKH 
holding in United States v. Caronia,44 and argued that drug
manufacturers should be allowed to provide information that consists
of solely truthful and non-misleading speech.45
While the FDA did attempt to make concessions allowing for some
dissemination of information without the risk of criminal
prosecution, they objected to the preliminary injunction.46 They
offered that providing the results of the ANCHOR study would not
put Amarin under threat of prosecution,47 but making statements
about the off label use of Vascepa was a violation that directly struck
39.Amarin Pharma, 119 F. Supp. 3d at 212.
40. Id.
41.See generally ³Off Label´ and Investigational Use of Marketed Drugs, Biologics, and Medical Devices ± Information Sheet, US Food and Drug Administration
Regulatory Information, (Jan. 25, 2006),
http://www.fda.gov/RegulatoryInformation/Guidances/ucm126486.htm (The FDA
does not regulate physicians in the prescribing of drugs, so they are able to
prescribe drugs for usage that are not FDA approved.).
42.Amarin Pharma, 119 F. Supp. 3d at 212.
43.Id. at 213.
44.See United States v. Caronia, 703 F.3d 149, 169 (2d Cir. 2012) (holding that
³the government cannot prosecute pharmaceutical manufacturers and their
representatives under the FDCA for speech promoting the lawful, off-label use of
an FDA-approved drug.´).
45.Amarin Pharma, 119 F. Supp. 3d at 198.
46.Id. at 216.
47. Id.
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at the heart of the principles of the drug approval framework
established by Congress in 1962.48 Further, the FDA claimed that
bringing a misbranding claim on promotional statements would not
³SUoKLELW VSHHFK´ DQG ZDV LQWHQGHG WR SURWHFW WKH SURPRWLRQ RI WKH
use of a drug that was not deemed safe and effective by the FDA.49
The FDA argued that while their enforcement was to be based on
speech alone, there are other crimes where criminal liability can
attach where speech is the only act.50 These acts include jury
tampering, blackmail, and insider trading.51
These arguments to obtain a preliminary injunction against any
enforcement actions by the FDA against Amarin were heard on July
7, 2015.52 In the hearing, the court considered the likelihood of
success of the case on its merits and granted the preliminary
injunction.53 The court held that a misbranding prosecution cannot
be based on free speech and that Amarin may engage in truthful and
non-misleading speech, and that based on the facts provided, the
information they wish to promote about Vascepa is truthful and
non-misleading.54
BACKGROUND
7KH )HGHUDO )RRG 'UXJ DQG &RVPHWLF $FW ³)'&$´  LV D VHW RI
laws passed by Congress in 1938 to oversee the safety of food, drugs,
and cosmetics.55 Congress gives authority to the FDA to oversee and
enforce this act.56
7KH)'$¶VHDUO\MXULVGLFWLRQIRFXVHGRQDFFXUDWHODEHOLQJRIGUXJV
and did not include safety or effectiveness.57 However, after some
VLJQLILFDQWSXEOLFKHDOWKGLVDVWHUVRFFXUUHGWKH)'$¶VUROHH[SDQGHG
48.Id. at 218.
49. Id.
50.Id. at 224.
51. Id.
52.Id. at 219.
53.Id. at 237.
54. Id.
55.Ventola, supra note 3, at 428.
56.See 21 USCS §§ 301 et seq.
57.Jerry Avorn,, Two Centuries of Assessing Drug Risks, 367 New Eng. J. Med.
193, 195 (2012).
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to protect the public from unsafe drugs.58 In 1937, more than 100
children had been poisoned by a sulfanilamide preparation that used a
substance known to be lethal.59 This resulted in a public that
demanded that the FDA ensure that drugs were safe for the public.60
Then, in 1962, more than 10,000 children worldwide were born with
ELUWK GHIHFWV DV D UHVXOW RI WKHLU SUHJQDQW PRWKHU¶V XVH RI
Thalidomide.61 Public outcry led to further legislation, giving the
FDA the rights to ensure drug effectiveness as well as drug safety.62
Obtaining FDA approval is a long, costly and complex process and
it can take decades before a drug can be used in the market and
prescribed by physicians.63 The labeling, marketing, and promotion
of the drug in the market is limited to the FDA approved uses. 64 If
new uses are found but not FDA approved, the use is referred to as
µRIIODEHO¶XVH65 While promotion of off label uses is limited by the
FDCA, off label prescribing by physicians is not.66 A physician may
use their medical judgment to prescribe drugs for uses not approved
by the FDA, but pharmaceutical companies cannot label or promote
the drugs for those uses.67
Off label uses can be shared with physicians in limited ways.
Scientific studies may be published by manufacturers in peer
reviewed scientific journals or through presentation of journal
articles, or through trainings and workshops through independent
sources not funded and not sponsored or presented by the

58. Id.
59. Id.
60. Id.
61.Id. at 196.
62. Id.
63.Fed. Drug Admin., The FDA¶s Drug Review Process: Ensuring Drugs Are Safe
and Effective (Nov. 6, 2014),
http://www.fda.gov/drugs/resourcesforyou/consumers/ucm143534.htm.
64.Ventola, supra note 3, at 432.
65.Amarin Pharma, 119 F. Supp. 3d at 200.
66.John E. Osborn, Can I Tell You the Truth? A Comparative Perspective on Regulating Off-Label Scientific and Medical Information, 10 Yale J. Health Pol¶y L. &
Ethics 299, 303 (2010), Available
at:http://digitalcommons.law.yale.edu/yjhple/vol10/iss2/2.
67.Amarin Pharma, 119 F. Supp. 3d at 200.
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manufacturer.68 To limit the promotion of off label uses, the FDA
prohibits the introduction of new drugs into interstate commerce if
their use has not been approved and the FDCA prohibits the
misbranding of drugs.69 $GUXJLVPLVEUDQGHGLILWVODEHOLQJLV³IDOVH
or misleadLQJ´70 While the FDCA defines labels as any material
accompanying the drug,71 WKH )'$¶V UHJXODWLRQV are more broadly
defined as anything a representative of the company or the product
might present with the drug, or about the drug, even if it does not
accompany the drug itself.72 The FDA requires that pharmaceutical
companies limit statements relating to the promotion of their drugs to
the use for which the drug was approved.73 Therefore, off label use
would never be allowed for new drugs, and promotion of off label
uses for existing approved drugs are limited through the FDCA
limitations on misbranding and information dissemination of
unapproved uses.
The FDA has litigated many cases against pharmaceutical
manufacturers such as Allergan, GlaxoSmithKline, and Abbott that
have violated the misbranding prohibition found in the FDCA.74
These cases have resulted in billions of dollars in criminal and civil
settlements.75
A complaint was filed in 2007 against Allergan for off-label
marketing of pharmaceuticals.76 Two other complaints followed in
2008 and 2009, and in 2010, Allergan pled guilty and paid $600
million in fines, including $375 million in criminal fines, and $225
million in civil fines for the unlawful promotion of Botox®
Therapeutic, for uses not approved as safe and effective by the
FDA.77 Amongst such unapproved conditions are headache, pain,
68.Ventola, supra note 3, at 429.
69.21 U.S.C.A. § 331 (West 2013).
70.21 U.S.C.A. § 352 (West 2013).
71.21 U.S.C.A. § 321 (West 2009).
72.Food and Drugs, 21 C.F.R. § 202.1 (2009).
73.21 U.S.C.A. § 331 (West 2015).
74.Amarin Pharma, 119 F. Supp. 3d at 204.
75. Id.
76.Complaint, U.S. v. Allergan, Inc., No. 1-07-CV-1288 (D. Ga. Jun. 5, 2007).
77.Dep¶t of Justice, Allergan Agrees to Plead Guilty and Pay $600 Million to Resolve Allegations of Off-Label Promotion of Botox® (Sept. 1, 2010),
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spasticity and juvenile cerebral palsy.78 Allergan was particularly
egregious in its promotion for pain and headaches as they increased
the number of staff-held workshops held for physicians and practices
focused on diagnosing and billing for Allergan for these uses.79
In 2011, a complaint was filed against GlaxoSmithKline for,
amongst other things, proPRWLQJ SURGXFWV ZKLFK WKH ³)'$ KDG QRW
GHHPHGVDIHDQGHIIHFWLYH´80 In 2012, GlaxoSmithKline pled guilty
and paid $3 billion to settle cases associated with promoting
misbranded drugs including Paxil and Wellbutrin.81 In this case,
although the FDA never approved Paxil for pediatric use, GSK was
promoting Paxil depression in patients under age 18.82 GSK also was
routinely promoting Wellbutrin for a wide variety of lucrative off
label uses including weight-loss, sexual dysfunction, and ADHD and
substance addictions.83 For these two drugs, GSK paid criminal fines
of $757,387,200.84
Similarly, criminal charges were filed against Abbott Laboratories
in 2012 for misbranding of Depakote.85 Abbot settled for $1.5
million in 2012 for promoting uses of Depakote that were not
deemed safe and effective by the FDA.86 Specifically they were

http://www.justice.gov/opa/pr/allergan-agrees-plead-guilty-and-pay-600-millionresolve-allegations-label-promotion-botox.
78. Id.
79. Id.
80.Complaint, U.S. v. GlaxoSmithKline, PLC., C.A. No. 11-10398-RWZ (D. Mass.
Oct. 26, 2011).
81.Dep¶t of Justice, GlaxoSmithKline to Plead Guilty and Pay $3 Billion to Resolve
Fraud Allegations and Failure to Report Safety Data, (Jul. 2, 2010),
http://www.justice.gov/opa/pr/glaxosmithkline-plead-guilty-and-pay-3-billionresolve-fraud-allegations-and-failure-report.
82. Id.
83. Id.
84. Id.
85.Complaint, U.S. v. Abbott Laboratories, No. 1:12:CR26 (W.D. Va., May 7,
2012).
86.Dep¶t of Justice, Abbott Labs to Pay $1.5 Billion to Resolve Criminal & Civil
Investigations of Off-label Promotion of Depakote, (May 6, 2012),
http://www.justice.gov/opa/pr/abbott-labs-pay-15-billion-resolve-criminal-civilinvestigations-label-promotion-depakote.
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promoting Depakote for the treatment of agitation in dementia
patients and for schizophrenia.87
In addition to financial settlements for civil and criminal penalties,
criminal charges have been brought against sales representatives for
promotion of off label uses. First amendment defenses against the
FDA where criminal sentences have been levied are not always
upheld based on a free speech argument. In United States v. Caputo,
a federal appeals court in Chicago rejected a First Amendment claim
of a defendant sentenced to ten years in prison for marketing a
medical device to hospitals.88 This medical device was similar to an
approved device, but did not operate the same.89 The FDA had only
approved the companion product that worked differently, and did not
approve the new device for any use at all.90 The court held that this
was not an off-label promotion, and thus was not a free speech issue
that might receive constitutional protection under the first
amendment.91 They held that this was simply an unlawful sale and
upheld the criminal charges.92
More recently, however, there has been a case where the defendant
has been convicted of criminal charges for unlawful promotion of
drugs, and the courts held that preventing his promotion of the drugs
violated the deIHQGDQW¶V IUHH VSHHFK ULJKWV93 In this case, United
States v. Caronia in 2012, Caronia, a pharmaceutical sales
representative, appealed a criminal conviction for promoting off-label
uses of Xyrem, a prescription drug manufactured by Orphan Medical,
Inc.94 Caronia was subjected to a $25 fine and 100 hours of
community service.95 The Second Circuit ruleG WKDW WKH )'$¶V
enforcePHQW RI )'&$ YLRODWHG &DURQLD¶V )LUVW $PHQGPHQW ULJKWV
stating: ³:H FRQFOXGH VLPSO\ WKDW WKH JRYHUQPHQW FDQQRW SURVHFXWH
pharmaceutical manufacturers and their representatives under the
87. Id.
88.
89.Id. at 937.
90. Id.
91. Id.
92.Id. at 940.
93.United States v. Caronia, 703 F.3d 149, 152 (2d Cir. 2012).
94. Id.
95.Id. at 160.
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FDCA for speech promoting the lawful, off-label use of an
FDA-DSSURYHGGUXJ´96 The Second Circuit found the regulation is
PRUHH[WHQVLYHWKDQLVQHFHVVDU\WRVHUYHWKHJRYHUQPHQW¶VLQWHUHVW
97
The government did not appeal this ruling, and set in play a
holding that established the foundation from which Amarin was
decided.
AMARIN LEVERAGED THE CARONIA HOLDING
$PDULQ¶V UHTXHVW IRU D SUHOLPLQDU\ LQMXQFWLRQ ZDV EDVHG VTXDUHO\
on the holding in Caronia. Amarin argued that promotion of off label
uses of Vascepa was truthful speech, and the court in Caronia
established that this was protected speech under the first
amendment.98 The government argued that the holding in Caronia
applied only to the facts and circumstances of that case and was not a
general ruling.99 However, in Caronia, the court closely analyzed
and then deWHUPLQHG WKDW &DURQLD ZDV SURVHFXWHG IRU KLV ³VSHHFK´
DQG WKH VLPSOH SURPRWLRQ RI D GUXJ¶V RII-label use.100 The court
concluded he was, and vacated the conviction.101 By doing the free
speech analysis, the court in Caronia was taking a categorical view of
the case, rather than resting their holding based on any specific facts.
The Caronia court held that the misbranding provisions in the FDCA
could not reach into limiting truthful speech, which is protected by
the first amendment.102 Given thLV EDFNJURXQG WKH JRYHUQPHQW¶V
contention in Amarin that the Caronia holding was fact-based was
not supported by the court.103
This holding, whether narrowly fact-based or broadly applicable,
does not apply to all speech about uses of drugs. The claims must be
truthful and not misleading. In Caputo, the uses that were promoted
had not been substantiated by evidence or a study, but in Amarin,
there was a valid study and the uses promoted were true. In Amarin,
96.Id. at 169.
97.Id. at 167.
98.Amarin Pharma, 119 F. Supp. 3d at 219.
99.Id. at 224.
100.Caronia, 703 F.3d at 162.
101.Id. at 169.
102.Id. at 168.
103.Amarin Pharma, 119 F. Supp. 3d at 224.
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the ANCHOR-SPA studies were completed and were valid and FDA
approved studies. Any claims they intended to use to promote
Vascepa were based on valid studies and would be truthful, thus
protected by the first amendment.
IMPLICATIONS OF ALLOWING OFF LABEL PROMOTION
Benefits
There are many advantages gained by allowing broader promotion
of truthful, off label uses of drugs. Even today, data studying 725
million prescriptions showed that 20% of these prescriptions were for
off label uses.104 Seventy percent of those 20%, or over 100 million
prescriptions, were based on no or weak science.105 Still, physicians
are choosing to prescribe based on information available to them,
even without this foundation.
Broader promotion allows data to be available to a wider range of
physicians that might otherwise not have been able to do the research
themselves. Physicians cannot keep current on all new research
available, even if they are published in journals. There are many
manufacturers and journals and a physician cannot reasonably be
expected to know all possible uses of every medication. Important
studies that may apply to their patients may easily be missed.106
Another argument for allowing off label promotion is to encourage
DQG VXSSRUW LQQRYDWLRQ LQ SK\VLFLDQ¶V FOLQLFDO SUDFWLFHV :LWKRXW
off-label promotion, manufacturers have little incentive to do
research to support paWLHQWVZLWK³RUSKDQGLVHDVHV´ WKRVHWKDWDIIOLFW
fewer than 200,000 Americans such as ALS or cystic fibrosis).107
The market is small, and without the ability to promote the uses in
orphan diseases, these drugs may not be known by physicians to be
used in their practice to support patients with no other alternatives.

104.David C. Radley, Susan N. Finkelstein & Randall S. Stafford, Off-label
Prescribing Among Office-Based Physicians, 166 Arch Intern Med 1021 (2006),
available at http://archinte.jamanetwork.com.
105.Id.
106.Ventola, supra note 3, at 432.
107.Id.
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More commonly, the argument for the promotion of off label uses
prior to FDA approval is to provide early notification to physicians
about uses that have been studied and proven. Even with new and
more efficient processes to fast-track drug approval, the process
could take years, making effective treatments unavailable to patients
who need them.108 The impact of this could be tragic. Patients that
could benefit from uses, validated by studies outside the FDA
approval process, may die or decline significantly before the uses of
the drugs are known. In patients who have died, or where there is no
reversal of disease progression possible, it would be tragic not to
make these drug usages known to their physicians as early as
possible to slow or prevent decline, manage symptoms, or prevent or
delay death.
Risks
Despite these advantages, the unfettered promotion of even truthful
information raises concerns.
Promotion of drug uses through peer-reviewed articles may
introduce unintended consequences that expose the profession to
risks and vulnerabilities, and thus introduce safety risks to the public.
These concerns include the risks of selective publication of only
positive studies, the suppression of important safety data, ghost
written articles, and increased focus on publishing for the purposes of
promoting reprints for marketing.109
Other concerns are that while off label promotion will ensure
broader availability of the alternative uses and data to physicians, it
does not follow that physicians will do their own due diligence to
seek out additional information or do further research. In these cases,
physicians may rely solely on the information provided by the
pharmaceutical manufacturer where the FDA has not compelled more
rigorous research and proof of effectiveness. This may result in false
confidence by physicians who may prescribe drugs that have limited
effectiveness or pose other risks to the patient.

108.United States v. Caronia, 703 F.3d 149, 162 (2d Cir. 2012).
109.Ventola, supra note 3, at 435.
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There are also questions about whether the FDA has enough
resources to ensure that this widespread promotion is based on
truthful content. The government does not have an unlimited amount
of resources, and by not placing clearly defined limits on promotion,
such as containing broad promotion to FDA approved uses of drugs,
the public health may be at risk.110
Another concern is whether the ability to widely promote off-label
uses of drugs provides a motivation for drug manufacturers to avoid
doing extensive clinical trials required by the FDA prior to promoting
to physicians. There is concern that drug manufacturers may initially
conduct trials for a narrower, less complex use of a drug, as a way to
get the drug into market, and then promote the off-label uses without
the extensive testing normally required.111 This situation occurred
with Fenfluramine when it was used in combination with
Phentermine (fen-phen) for weight loss and resulted in thousands of
people with heart valve damage.112 Fenfluramine was approved as an
appetite suppressant, and there were not extensive clinical trials for
the fen-phen combination that would have identified this risk and
prevented this long term heart damage.113
Recent studies have shown that the risks are very real. In a study
published on November 2, 2015, in the journal JAMA Internal
Medicine, researchers at McGill University in Toronto found that
patients were fifty-four percent more likely to experience adverse
events if they were prescribed a drug for off label use. 114 This is
particularly concerning given the prevalence of off label prescriptions
written.
IS IT A TRAP?
The pharmaceutical companies certainly find that the ruling in
Amarin may benefit their ability to communicate the off-label,
110.Id. at 438.
111.Id. at 431.
112.Id. at 428±440.
113.Id.
114.Karen Pallarito, Beware Safety Risks Posed by µOff-Label¶ Drug Use,
HEALTHDAY, (Nov. 2, 2015), http://consumer.healthday.com/general-healthinformation-16/prescription-drug-news-551/beware-safety-risks-posed-by-offlabel-drug-use-704854.html.
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unapproved truthful uses of drugs more broadly to the public and
physicians. With the ruling in Amarin, it appears that this speech is
protected by the first amendment and the risk of prosecution and
large fines is at least minimized.
Shortly after the Amarin ruling, other pharmaceutical
manufacturers began to seek relief from the threat of criminal
prosecution similar to Amarin. Pacira Pharmaceutical filed a
complaint on September 8, 2015 in the same court regarding
EXPAREL, PaciUD¶VORFDODQHsthetic product, asking the court to deFODUHWKDWWKH)'$PD\QRWOLPLW3DFLUD¶VFRPPXQLFDWLRQDVLWLVIUHH
speech, and to declare an FDA warning letter arbitrary and
capricious.115 The parties settled and the letter was withdrawn on
December 14, 2015.116
Nonetheless, it is unclear how broad this ruling is. While certainly
a win for first amendment protected free speech, the ruling is one that
protects truthful speech. In the Amarin ruling, the court looked
closely at the wording Amarin wished to use.117 The holding
concluded that Amarin may promote truthful speech, but concluded
this based on the evaluation of the information provided to the
court.118 If pharmaceutical companies determine independently that
their research can be conclusively viewed as truthful, are they then
subject to similar judicial review? Until this case concludes, or
additional cases go forward, we will not know whether this ruling is
fact specific to the Amarin case. Companies that act based on this
ruling without further judicial holdings are at risk for negative
evaluations of their claims and losses in the courtroom. Until the full
precedential value of this holding is determined, drug makers should
be wary of believing that this holding opens up broad off label
promotion opportunities.

115.Complaint of Plaintiff, Pacira Pharmaceuticals, Inc. et al v. United States
Food & Drug Administration et al, 15-cv-07055 (2015)(LAK).
116.Letter from Janet Woodcock, M.D., Director, Center for Drug Evaluation and
Research, FDA, to David Stack, CEO and Chairman, Pacira Pharmaceuticals (Dec.
14, 2015), available at http://media.corporateir.net/media_files/IROL/22/220759/The_Warning_Letter_Withdrawal_Letter.pdf.
117.Amarin Pharma, 119 F. Supp. 3d at 229.
118.Id. at 237.
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WHERE SHOULD THIS GO?
The need for off label usage of drugs is inarguable. Some studies
have found that the frequency of off label prescribing of drugs is as
much as 38.9% of all prescriptions.119 This varies by the type of
medication, but there is no question that physicians find off label
prescribing necessary. Drug makers should be able to promote off
label uses of drugs, but it must be done in a safe framework that is
less onerous than the full path of FDA approval.
Off label promotion of drugs should be limited to those uses where
there is clear evidence to support the claims. While the FDA has
made progress in providing faster drug approval paths,120 there still
must be a way to provide information to physicians for uses that have
been found to be useful, particularly for orphan diseases, which may
not normally have a broad enough impact on the population to invest
in even the faster approval processes. The FDA needs guidelines on
what evidence pharmaceutical companies must provide when they
promote off label uses and not limit the evidence to only FDA
approved studies.
Physicians must also have training or requirements through their
licensing or medical societies to ensure they are doing proper
diligence in investigating the uses of off label uses of drugs before
prescribing, and are informing their patients of the off label uses and
risks. While malpractice risks provide some incentive to physicians
to do further research before prescribing, desperation to help a patient
or unmanageable workloads may mean that the ph\VLFLDQWRGD\LVQ¶W
doing enough research to better understand the uses and risks before
prescribing.
Patients have a right to know about the medications that are
available in the market that have evidence indicating that the
medication could help them. With this right to knowledge comes the
119.John L. Turner, W. David Bradford, and Jonathan W. Williams, ³Off-Label
Use of Pharmaceuticals: Trends and Drivers´ ( July 23, 2015). Society for Economic Measurement Annual Conference. Paper 90. Available at
http://repository.cmu.edu/sem_conf/2015/full_schedule/90.
120.Fast Track, Breakthrough Therapy, Accelerated Approval, Priority Review,
(2015), http://www.fda.gov/forpatients/approvals/fast/ucm20041766.htm.

2016 BIOTECHNOLOGY & PHARMACEUTICAL LAW REVIEW 67
responsibility of the patients to ask about the supporting evidence of
the drug use for their illness and learn of the risks.
Off label marketing of drugs serves an important role in treating
illnesses where there is no medication approved to help the patient.
It should be allowed with a combination of regulation, information
availability, and physician and patient education.
THE PATH FORWARD
The parties in the Amarin case were issued an order on August 10,
2015 to jointly submit the next steps to the court by August 28,
2015.121 In response to that order, the parties asked the court for a
stay until October 30, 2015, which was extended until December 17,
2015 while they considered a settlement.122 This stay was later
extended until February 17, 2016.123 A proposed stipulation and
order of settlement was filed with the FDA on March 8, 2016.124 If
apSURYHGWKLVZLOOFORVH$PDULQ¶VFKDOOHQJHWRWKH)'$
While this settlement may be approved soon, the question remains
whether the approval of the injunction has precedential value. On
this subject, they then will have settled with Amarin, and with Pacira.
It seems that they will attempt to settle where they are challenged in
an effort to delay firmer grounding in the expansion of off label
promotions.

121.Amarin Pharma, Inc. v. U.S. FDA, 119 F. Supp. 3d 196 (2015) (No. 15 Civ.
3588),
http://www.lifescienceslegalupdate.com/wpcontent/uploads/sites/500/2015/08/15cv
03588Doc74.pdf.
122.Letter filed by Floyd Abrams, Attorney to Hon. Paul A. Engelmayer, United
States District Court Judge (10/30/2015),
http://www.lifescienceslegalupdate.com/wpcontent/uploads/sites/500/2015/08/15cv03588_Doc78.pdf.
123.Letter filed by Peter Gottesfeld, Amarin Pharma, Inc., Eric Rishe, Ralph Yung,
Jonathan Herbst to Hon. Paul A. Engelmayer, United States District Court Judge
(12/17/2015).
124.[Proposed] Stipulation and Order of Settlement, Amarin Pharma, Inc. v. U.S.
FDA, 119 F. Supp. 3d 196 (2015)(No. 15 Civ. 3588),
http://www.fdalawblog.net/AMRN%20Off-Label%20Proposed%20Settlement.pdf

